We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.66B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.66B
AUM Growth
+$327M
(+24%)
Cap. Flow
+$308M
Cap. Flow
% of AUM
18.5%
Top 10 Holdings %
Top 10 Hldgs %
40.47%
Holding
329
New
71
Increased
98
Reduced
59
Closed
29
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 90.27% |
| 2 | Financials | 1.54% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Teva Pharmaceuticals
TEVA
$37.6B
| $8.08M | 0.49% |
268,391
+32,420
| +14% | +$1.04M |
|
52
Savara
SVRA
$1.17B
| $8M | 0.48% |
1,464,535
+59,083
| +4% | +$329K |
|
|
MPLT
53
MapLight Therapeutics
MPLT
$1.71B
| $7.62M | 0.46% |
+374,909
| New | +$6.71M |
|
|
LONA
54
LeonaBio Inc
LONA
$76.3M
| $7.48M | 0.45% |
727,481
+333,780
| +85% | +$2.17M |
|
55
Equillium
EQ
$162M
| $7.45M | 0.45% |
3,726,659
-1,881,419
| -34% | -$3.1M |
|
56
Viking Therapeutics
VKTX
$4.32B
| $7.41M | 0.45% |
227,717
+201,223
| +760% | +$6.47M |
|
|
DMRA
57
Damora Therapeutics
DMRA
$1.87B
| $7.23M | 0.43% |
+279,000
| New | +$7.17M |
|
58
UroGen Pharma
URGN
$1.95B
| $7.11M | 0.43% |
395,459
+270,084
| +215% | +$5.41M |
|
59
BridgeBio Pharma
BBIO
$16.1B
| $7M | 0.42% |
94,292
-119,122
| -56% | -$8.63M |
|
60
Prime Medicine
PRME
$592M
| $6.87M | 0.41% |
+1,973,282
| New | +$7.51M |
|
61
PUT
iShares Russell 2000 ETF
IWM
$83B
| $6.82M | 0.41% |
27,500
| – | – |
|
62
Vertex Pharmaceuticals
VRTX
$122B
| $6.73M | 0.4% |
15,075
+1,359
| +10% | +$634K |
|
63
Korro Bio
KRRO
$183M
| $6.11M | 0.37% |
+540,054
| New | +$5.95M |
|
64
Viridian Therapeutics
VRDN
$2.01B
| $5.95M | 0.36% |
304,422
+227,224
| +294% | +$6.75M |
|
65
Danaher
DHR
$145B
| $5.86M | 0.35% |
30,932
+5,332
| +21% | +$1.14M |
|
66
Insmed
INSM
$23.3B
| $5.79M | 0.35% |
+35,392
| New | +$5.44M |
|
67
Ascendis Pharma A/S
ASND
$17.4B
| $5.72M | 0.34% |
25,014
-300
| -1% | -$67.3K |
|
68
Brighthouse Financial
BHF
$3.75B
| $5.72M | 0.34% |
95,523
| – | – |
|
69
Sarepta Therapeutics
SRPT
$1.85B
| $5.7M | 0.34% |
262,058
+233,192
| +808% | +$4.51M |
|
|
OACCU
70
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
| $5.5M | 0.33% |
516,482
| – | – |
|
|
PCSC
71
Perceptive Capital Solutions
PCSC
$123M
| $5.48M | 0.33% |
499,581
+42,861
| +9% | +$547K |
|
72
Krystal Biotech
KRYS
$10.3B
| $5.17M | 0.31% |
20,014
| – | – |
|
73
Acumen Pharmaceuticals
ABOS
$155M
| $5.09M | 0.31% |
2,156,334
+1,265,151
| +142% | +$3.23M |
|
74
Invivyd
IVVD
$235M
| $4.97M | 0.3% |
3,822,427
-76,970
| -2% | -$141K |
|
|
BHAVU
75
BHAV Acquisition Corp Units
BHAVU
| $4.93M | 0.3% |
+495,000
| New | +$4.93M |
|
Similar funds
GWM
GACM
RIA
CPO
NRI
JPM
GC
FA